Biogen Idec has announced that the FDA has on 15 August 2014, approved Plegridy (peginterferon beta-1a), a new treatment for...
Biogen Idec announced that the European Commission (EC) has on 23 July 2014 granted marketing authorization for Plegridy (peginterferon beta-1a)...
Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis (see section 5.1).
Biogen Inc. announced that the European Commission (EC) has approved a new intramuscular (IM) injection route of administration for Plegridy (peginterferon beta-1a) for the treatment of relapsing-remitting multiple sclerosis (MS).
Biogen Idec has announced it has submitted a Biologics License Application (BLA) to the FDA for approval of Plegridy (peginterferon...
Biogen Idec received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
Biogen Inc. announced that the FDA has approved a new intramuscular (IM) injection route of administration for Plegridy (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS).